Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir
Status:
Completed
Trial end date:
2017-01-26
Target enrollment:
Participant gender:
Summary
Oral administration has many advantages above intravenously administrated drugs for patients.
Up to now, oral administration of docetaxel as single agent has not been feasible due to low
and variable bioavailability. This low systematic exposure to docetaxel can effectively be
increased after co-administration of ritonavir. The department of pharmacy of the Slotervaart
Hospital and Netherlands Cancer Institute developed a solid oral dosage form for docetaxel,
ModraDoc001 10 mg capsules.
Two other novel dosage forms of docetaxel with improved pharmaceutical characteristics, have
been developed: ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets. The systemic
exposure after administration of those forms is now being investigated.